{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-086190","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-08-06T20:40:40+00:00","discovered_at":"2026-08-06T20:42:31.851232+00:00","generated_at":"2026-08-06T20:42:47.572287+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada reports Q2 net loss $12.9M; cash $217.7M; NDV-01 IND on track for YE26","bullets":["Net loss of $12.9M ($0.11/share) vs $9.9M loss in Q2 2025; R&D expense rose to $8.4M from $2.8M.","Cash, equivalents, and short-term investments of $217.7M as of June 30, 2026, expected to fund operations through 2029.","NDV-01 IND filing expected by year-end 2026; Phase 3 RESCUE program initiation upon IND clearance.","Sepranolone IND filing expected by year-end 2026; Phase 2 proof-of-concept in Prader-Willi Syndrome upon clearance.","Appointed Bipin Dalmia as Chief Business Officer; added to Russell 2000 and 3000 indexes in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-086190","json":"https://secwatch.observer/filing/0001213900-26-086190.json","markdown":"https://secwatch.observer/filing/0001213900-26-086190.md","text":"https://secwatch.observer/filing/0001213900-26-086190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/0001213900-26-086190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:42:47.572287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}